What problem does this paper attempt to address?

The problem this paper attempts to address is the development of a highly selective covalent inhibitor for EZH2. Specifically, the researchers aim to design and synthesize a compound that can specifically inhibit EZH2 without affecting EZH1 and other methyltransferases by targeting the unique cysteine 663 (Cys663) residue in EZH2. This selective inhibitor can not only be used to treat diseases driven by EZH2 but also serve as a chemical probe to further study the specific role of EZH2 in cancer and other related diseases. ### Main Research Background and Motivation: 1. **Function and Importance of EZH2**: - EZH2 is a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), responsible for catalyzing the trimethylation of lysine 27 on histone H3 (H3K27Me3), an epigenetic mark for transcriptional repression. - Dysfunction of EZH2 is associated with various malignancies and poor prognosis. - EZH2 and EZH1 are highly homologous in structure, but they have significant functional differences, especially during development and cell differentiation. 2. **Limitations of Existing EZH2 Inhibitors**: - Most of the currently developed EZH2 inhibitors inhibit both EZH1 and EZH2, lacking selectivity. - These non-selective inhibitors may cause unnecessary side effects since EZH1 also plays important roles in certain physiological processes. 3. **Research Objectives**: - Develop a highly selective covalent inhibitor for EZH2 to overcome the selectivity issues of existing inhibitors. - Achieve high selectivity inhibition of EZH2 by targeting the unique Cys663 residue in EZH2. ### Research Methods and Results: 1. **Compound Design and Synthesis**: - By aligning the sequences of EZH2 and EZH1, Cys663 was identified as an effective target. - A series of indole derivatives containing charged head groups were synthesized, and the activity of the compounds was optimized through structure-activity relationship studies. 2. **Evaluation of Compound Activity and Selectivity**: - The compound SKLB-0335 was screened and found to have high selectivity and potent inhibitory effects on EZH2. - Molecular dynamics simulations, competition experiments, and mass spectrometry analysis confirmed that SKLB-0335 inhibits EZH2 by forming a covalent bond with Cys663. 3. **Biological Effects Evaluation**: - At the cellular level, SKLB-0335 effectively reduced H3K27Me3 levels, and its inhibitory effect was time- and concentration-dependent. - SKLB-0335 did not significantly inhibit EZH1, indicating its high selectivity. ### Conclusion: SKLB-0335 is an efficient and selective covalent inhibitor of EZH2, which can be used to study the specific role of EZH2 in cancer and other related diseases, and it may also become a potential drug for treating EZH2-driven diseases.

The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor

Covalent inhibitors of EZH2: Design, synthesis and evaluation

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas

Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2

Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity

Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2

Focus on the classical and non-classical functions of EZH2: Guide the development of inhibitors and degraders

Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas

Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer

Novel Natural Inhibitors Targeting Enhancer of Zeste Homolog 2: A Comprehensive Structural Biology Research

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

Development of a high-throughput fluorescence polarization assay for the discovery of EZH2-EED interaction inhibitors

Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma

Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2

Design, Synthesis, and Evaluation of VHL-based EZH2 Degraders for Breast Cancer